Editorial: Lipids, lipoproteins and COVID-19.

Front Cardiovasc Med

Cardiovascular Division, Department of Medicine, Washington University School of Medicine, St. Louis, MO, United States.

Published: November 2023

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10646584PMC
http://dx.doi.org/10.3389/fcvm.2023.1293249DOI Listing

Publication Analysis

Top Keywords

editorial lipids
4
lipids lipoproteins
4
lipoproteins covid-19
4
editorial
1
lipoproteins
1
covid-19
1

Similar Publications

We previously reported that plasmalogens, a class of phospholipids, were decreased in a setting of dilated cardiomyopathy (DCM). Plasmalogen levels can be modulated via a dietary supplement called alkylglycerols (AG) which has demonstrated benefits in some disease settings. However, its therapeutic potential in DCM remained unknown.

View Article and Find Full Text PDF

We investigated several small viral proteins that reside and function in cellular membranes. These proteins belong to the viroporin family because they assemble into ion-conducting oligomers. However, despite forming similar oligomeric structures with analogous functions, these proteins have diverse amino acid sequences.

View Article and Find Full Text PDF

Young Adults with Type 1 Diabetes' Clinical Outcomes and Satisfaction Related to the Use of Videoconferencing for Type 1 Diabetes Healthcare: A Narrative Review.

Diabetes Ther

January 2025

Departamento de Endocrinología y Metabolismo, Unidad de Investigación en Enfermedades Metabolicas, Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán, Mexico City, Mexico.

Introduction: Young adulthood is well documented as being a particularly challenging area of type 1 diabetes (T1D) healthcare. Many young adults with T1D (YAT1D) are distracted from effective disease self-management; T1D healthcare service engagement can be problematic and inconsistent, and high rates of unplanned healthcare contacts prevail. Video conferencing use can facilitate services to be flexible and responsive.

View Article and Find Full Text PDF

Differential Inhibition by Cenobamate of Canonical Human Nav1.5 Ion Channels and Several Point Mutants.

Int J Mol Sci

January 2025

Department of Anatomy, Animal Physiology and Biophysics, Faculty of Biology, University of Bucharest, Splaiul Independentei 91-95, 050095 Bucharest, Romania.

Cenobamate is a new and highly effective antiseizure compound used for the treatment of adults with focal onset seizures and particularly for epilepsy resistant to other antiepileptic drugs. It acts on multiple targets, as it is a positive allosteric activator of γ-aminobutyric acid type A (GABA) receptors and an inhibitor of neuronal sodium channels, particularly of the late or persistent Na current. We recently evidenced the inhibitory effects of cenobamate on the peak and late current component of the human cardiac isoform hNav1.

View Article and Find Full Text PDF

Fanlian Huazhuo formula: A promising therapeutic approach for metabolic associated steatotic liver disease.

World J Gastroenterol

January 2025

Department of Biochemistry, School of Medicine, College of Medicine, China Medical University, Taichung 404328, Taiwan.

This article reviews the study, "Fanlian huazhuo formula alleviates high-fat-diet-induced nonalcoholic fatty liver disease by modulating autophagy and lipid synthesis signaling pathway" published in the . The study explores the therapeutic potential of Fanlian Huazhuo formula (FLHZF) in treating metabolic-associated steatotic liver disease (MASLD), demonstrating that FLHZF reduces lipid accumulation, oxidative stress, and liver injury in MASLD models by modulating key signaling pathways involved in lipid metabolism and autophagy. This editorial emphasizes the potential of FLHZF as a treatment for MASLD and calls for further research to verify its clinical efficacy.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!